Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug in Normal Healthy Volunteers
NCT07090655Phase 1Completed
- Sponsor
- Climb Bio
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Budoprutug with Placebo (2 arms). Primary endpoints: Safety and Tolerability of Single Ascending Doses at Day 57, Incidence of infusion-related reactions at Day 57 and 1 more. Started Aug 2025; status: completed.
02
Drugs
budoprutug
Beyond the preview
Go deeper on NCT07090655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090655.